Documentos relacionados

1. Real-world evidence: Long-term safety of deferiprone in a large cohort of patients with sickle cell disease enrolled in a registry for up to 10 years.
2. Chelation therapy for iron overload: nursing practice implications.
3. Diluting I.V. push medications: Risky business.
4. Efficacy and Safety of Iron Chelation Therapy After Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Thalassemia Patients: A Retrospective Observational Study.
5. Effects of renal impairment on the pharmacokinetics of orally administered deferiprone.
6. A case of post-splenectomy transfusion-dependent homozygous beta-thalassemia major complicated with myocardial siderosis and osteoporosis and usage of iron-chelating therapy with deferiprone in pregnancy.
7. Safety profiles of iron chelators in young patients with haemoglobinopathies.
8. Trial of Deferiprone in Parkinson's Disease.
9. Spin density projection-assisted R2 magnetic resonance imaging of the liver in the management of body iron stores in patients receiving multiple red blood cell transfusions: an audit and retrospective study in South Australia.
10. Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes.